ASTX030
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Arms / Cohorts
Experimental:Phase 1, Stage A (Dose Escalation)
Accepting patients
Experimental:Phase 1, Stage B (Dose Expansion)
Accepting patients
Experimental:Phase 2, Sequence A
Accepting patients
Experimental:Phase 2, Sequence B
Accepting patients
Experimental:Phase 3, Sequence A
Accepting patients
Experimental:Phase 3, Sequence B
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.